# Altria account plan

> Altria makes and sells US nicotine products, including Marlboro cigarettes, Copenhagen, on! pouches and NJOY e-vapor; FY2025 net revenues $23,279 million.

## At a glance

Altria Group, Inc., based in Richmond, Virginia, is a holding company whose operating companies make and sell nicotine products almost entirely in the United States: Philip Morris USA (cigarettes, including Marlboro), John Middleton (Black & Mild cigars), U.S. Smokeless Tobacco Company (Copenhagen and Skoal), Helix Innovations (on! nicotine pouches) and NJOY (e-vapor). Products go mainly to wholesalers and large retailers; one customer accounted for about 23% and another for about 19% of 2025 net revenues. In FY2025 net revenues were $23,279 million (-3.1%), reported net earnings $6,947 million and adjusted diluted EPS $5.42. Altria employed about 5,900 people at December 31, 2025 and holds equity stakes in ABI and Cronos.

## Business units

- **Smokeable products** (about 88% of FY2025 net revenues ($20,485 million)): PM USA cigarettes (Marlboro, Virginia Slims, Parliament, L&M, Basic) and Middleton cigars. Marlboro held 39.5% of the total cigarette category in Q3 2026 while discount share grew; nine-month 2026 adjusted OCI rose 4.1% to $8,766 million at a 64.8% margin.
- **Oral tobacco products** (about 12% of FY2025 net revenues ($2,802 million)): USSTC moist smokeless tobacco (Copenhagen, Skoal, Red Seal) and Helix on! nicotine pouches. Shipments fell 5.4% over nine months of 2026 as MST declined while on! grew 7.7%; nine-month adjusted OCI was $1,339 million (-4.0%).
- **E-vapor products (NJOY)**: NJOY ACE and NJOY Daily; NJOY ACE remains under an ITC exclusion order from JUUL patent litigation, and Altria recorded $2,128 million of e-vapor impairments in 2025. Since 2026 it sits in the all other category; Altria says it plans to re-enter the e-vapor market.
- **All other**: Horizon Innovations (75%-owned heated tobacco JV with Japan Tobacco, awaiting FDA authorisation of Ploom), Helix International (on! outside the US) and R&D on new product platforms.

## Strategic priorities

- **2028 Enterprise Goals**: Mid-single digits adjusted diluted EPS CAGR from a $4.87 base in 2022, progressive dividend growth in mid-single digits through 2028, debt-to-Consolidated EBITDA of about 2.0x and total adjusted OCI margin of at least 60% each year.
- **Grow on! in nicotine pouches**: Pouches reached 61.2% of the oral category in Q3 2026; on! PLUS 12 mg went national with new flavours, backed by a retail trade program in stores representing approximately 90% of its volume.
- **Defend Marlboro's premium position**: A data-driven, total portfolio approach uses Marlboro Cowboy Cut for value-sensitive smokers and Basic in discount; Marlboro held 60.0% of premium in Q3 2026.
- **Optimize & Accelerate**: Centralising work, outsourcing transactional activities and automating processes for cumulative savings of at least $600 million by end-2029, reinvested in the business.
- **Growth beyond the US and beyond nicotine**: Compete in top international innovative oral markets, develop heated tobacco and e-vapor abroad, and broadly distribute at least five non-nicotine products by 2028.

## Latest results

In Q3 2026 net revenues rose 1.0% to $6,132 million and adjusted diluted EPS 4.8% to $1.52. Over nine months net revenues were $17,671 million (+1.4%) and adjusted diluted EPS $4.33 (+5.1%), with higher pricing and duty refunds on contract-manufactured export cigarettes offsetting lower volume and mix toward discount. Domestic cigarette volume fell 2.8% over nine months. Full-year 2026 adjusted diluted EPS guidance was raised to $5.66 to $5.74, growth of 4.5% to 6.0% from $5.42 in 2025.

## Investments and deals

- **USSTC Facilities Consolidation**: Announced May 2026: Nashville, Tennessee manufacturing moves to a new plant on the Hopkinsville, Kentucky campus, substantially complete in Q1 2028, for about $180 million of pre-tax charges.
- **Capital expenditure**: 2025 capex rose 52.1% to $216 million for manufacturing capabilities and innovative products; 2026 capex is expected at $300 million to $375 million.
- **Contract manufacturing**: Contract-manufactured export cigarettes reached 2,941 million sticks over nine months of 2026 versus 786 million; 2026 guidance includes investments in contract manufacturing capabilities.
- **Shareholder returns**: Dividend raised 4.7% to $1.11 per quarter in August 2026; buybacks of $735 million over nine months and a $1 billion program expansion expiring December 31, 2027.

## Challenges and risks

- **Cigarette volume decline and trade-down**: Inflation-squeezed adult consumers move to discount; industry discount share reached 34.1% in Q3 2026 and Marlboro's total share fell 1.0 point.
- **Illicit e-vapor**: Illicit flavored disposables are estimated at about 70% of the e-vapor category, and Altria says enforcement is insufficient.
- **NJOY patent litigation**: The ITC exclusion order keeps NJOY ACE off the market, and guidance assumes it does not return in 2026.
- **MST decline and pouch competition**: Copenhagen and Skoal shipments fell 10.5% and 12.5% over nine months of 2026, while competitive investment in pouches remained elevated.
- **FDA regulation**: PMTA outcomes, a proposed maximum-nicotine standard and state flavour bans weigh on the portfolio; Helix and NJOY sued the FDA over authorization timelines.

## What leadership says

> "Altria delivered strong financial performance in the third quarter, growing adjusted diluted earnings per share by 4.8%, while continuing to invest in our Vision and building on our foundation for the future." — Sal Mancuso, Chief Executive Officer, Q3 2026 earnings release, October 29, 2026

> "Sustained progress on harm reduction requires a more durable foundation, an efficient and predictable authorization process established through rulemaking." — Sal Mancuso, Chief Executive Officer, Q3 2026 earnings call, October 29, 2026

> "We have not announced when we're going back in the market, but we do plan on being back in the evapor market" — Sal Mancuso, Chief Executive Officer, Q3 2026 earnings call, October 29, 2026

> "For harm reduction to succeed, 2 things are necessary, a more efficient authorization process and consistent enforcement over time." — Sal Mancuso, Chief Executive Officer, Q2 2026 earnings call, July 30, 2026


## Where a supplier can help

- **Process automation and outsourcing**: Optimize & Accelerate's outsourcing of transactional activities and automation, with at least $600 million of targeted savings, opens doors for automation and business-process service providers.
- **Manufacturing and plant build-out**: The USSTC move to Hopkinsville and higher 2026 capex for manufacturing and contract manufacturing favour equipment, engineering and construction suppliers.
- **Retail execution and trade marketing**: Growing on! PLUS through retail trade programs, events and paid social, and the data-driven Marlboro portfolio approach, call for retail analytics and trade marketing tools.
- **Regulatory and compliance support**: PMTA filings, FDA rulemaking and planned e-vapor re-entry create demand for regulatory science, testing and compliance services.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Altria Group Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/764180/000076418026000017/mo-20251231.htm)

Annual report · 2026-02-25

- Altria Group is a US-only nicotine holding company: PM USA (Marlboro cigarettes), John Middleton (Black & Mild cigars), USSTC (Copenhagen, Skoal MST), Helix (on! oral nicotine pouches) and NJOY (e-vapor), plus the Horizon heated-tobacco JV (75% Altria, 25% Japan Tobacco) and equity stakes in ABI and Cronos. About 5,900 employees at December 31, 2025.
- FY2025 net revenues were $23,279 million (down 3.1%); revenues net of excise taxes $20,139 million. Reported diluted EPS fell 37% to $4.12 (2024 included a $2.7 billion gain on the IQOS rights sale); adjusted diluted EPS rose 4.4% to $5.42.
- Smokeable products remain the profit engine: $20,485 million net revenues and $11,064 million adjusted OCI (63.4% margin), despite cigarette shipments falling 10.0% to 61.8 billion units; pricing more than offset volume.
- Oral tobacco products: $2,802 million net revenues, $1,835 million adjusted OCI (67.9% margin); retail share fell 5.4 points to 31.9% as nicotine pouches reached 53.3% of the US oral category and on!'s share of pouches fell to 15.4%.
- E-vapor (NJOY) lost $2,297 million of reported OCI, driven by $2,128 million of goodwill and intangible impairments: NJOY ACE is banned by an ITC exclusion order and illicit flavored disposables are about 70% of the e-vapor category. Smoke-free 2028 goals are being reassessed.
- 2028 Enterprise Goals: mid-single-digit adjusted EPS CAGR from a $4.87 2022 base (3.6% achieved through 2025), mid-single-digit dividend growth, debt/EBITDA of about 2.0x, adjusted OCI margin of at least 60%, and at least five non-nicotine products by 2028.
- Optimize & Accelerate initiative (centralisation, outsourcing, automation): cumulative savings of at least $600 million by end-2029, about $175 million of charges; capex rose 52.1% to $216 million in 2025 and is guided at $300-375 million for 2026.
- Cash returns: dividends of about $6,960 million in 2025, $1.0 billion buyback expansion; debt $25.7 billion, debt/Consolidated EBITDA 2.0.
- Leadership change: CEO William F. Gifford, Jr. retires at the May 14, 2026 annual meeting; CFO Salvatore Mancuso becomes CEO and Heather A. Newman becomes CFO.

### [Altria Group Form 10-Q for the third quarter of 2026](https://www.sec.gov/Archives/edgar/data/764180/000076418026000114/mo-20260930.htm)

Interim report · 2026-10-29

- Form 10-Q for Q3 2026: nine-month net revenues rose 1.4% to $17,671 million (Q3: $6,132 million, +1.0%); reported diluted EPS $4.18 (+21.2%, lapping the 2025 e-vapor goodwill impairment), adjusted diluted EPS $4.33 (+5.1%).
- Segments are now two: smokeable products and oral tobacco products. NJOY e-vapor moved into "all other" with Horizon, Helix International and R&D.
- Smokeable: adjusted OCI $8,766 million (+4.1%), margin 64.8%; domestic cigarette shipments -2.8% to 45,146 million sticks while discount (Basic, L&M) rose 69.7%; contract-manufactured export cigarettes jumped to 2,941 million sticks from 786 million.
- Refunds of taxes and duties paid on imported cigarettes added $182 million to smokeable OCI over nine months and cut excise taxes 10.8%.
- Oral: adjusted OCI $1,339 million (-4.0%), margin 66.8%; shipments -5.4% as Copenhagen (-10.5%) and Skoal (-12.5%) fell and on! grew 7.7% to 143.9 million cans; retail share 28.6% (-3.9 points); pouches reached 61.2% of the oral category in Q3.
- USSTC will move its Nashville manufacturing to a new facility in Hopkinsville, Kentucky by Q1 2028, with about $180 million of pre-tax charges ($87 million so far).
- FDA issued more on! MGOs in August 2026 (autumn spice, rich berry, cappuccino; 2 mg and 4 mg); NJOY ACE stays under the ITC ban; Horizon still has no product in market.
- Balance sheet: cash $2.7 billion, long-term debt $24.1 billion, debt/Consolidated EBITDA 1.9; quarterly dividend raised 4.7% to $1.11 ($4.44 annualised).

### [Altria reports 2026 third-quarter and nine-months results (earnings release)](https://www.sec.gov/Archives/edgar/data/764180/000076418026000112/exhibit991erq32026.htm)

Interim report · 2026-10-29

- Q3 2026 earnings release (October 29, 2026): adjusted diluted EPS +4.8% to $1.52 and reported diluted EPS +7.1% to $1.51; nine-month adjusted diluted EPS +5.1% to $4.33.
- Net revenues rose 1.0% to $6,132 million in Q3; revenues net of excise taxes rose 3.6% to $5,441 million.
- 2026 guidance raised: adjusted diluted EPS of $5.66 to $5.74, growth of 4.5% to 6.0% from $5.42 in 2025. The guidance assumes NJOY ACE does not return to market in 2026.
- Smokeable products adjusted OCI +3.9% in Q3 (margin 64.5%), on higher pricing and refunds of duties on imported cigarettes; Marlboro held 60.0% of the premium segment.
- Oral tobacco adjusted OCI -3.7% in Q3 (margin 66.4%) as on! PLUS investment and MST declines weighed.
- Helix added Blueberry Mint and Mango Pineapple to on! PLUS across 6, 9 and 12 mg; Watermelon Mint follows in Q4 in select stores.
- Cash returns: 5.9 million shares bought back in Q3 for $400 million; a further $1 billion buyback expansion runs to December 31, 2027; the August dividend increase was the 61st in 57 years ($4.44 annualised).
- CEO Sal Mancuso credits PM USA's "data-driven, total portfolio approach", with Cowboy Cut strengthening Marlboro and Basic gaining in discount.

### [Altria Q3 2026 earnings call transcript](https://www.earningswhispers.com/transcript/MO/Q32026)

Executive talk · Sal Mancuso, Chief Executive Officer · 2026-10-29

- Q3 2026 call (October 29, 2026), CEO Sal Mancuso and CFO Heather Newman. Guidance was raised from an initial 2.5% to 5% to 4.5% to 6% adjusted EPS growth after a strong nine months.
- on!: Q3 shipments +13.3% to 47.8 million cans, retail share 8.3%; on! PLUS 12 mg went national, new flavours (Blueberry Mint, Mango Pineapple, Watermelon Mint in November) and a retail trade program securing premium positioning in stores with about 90% of its volume.
- Regulation: Helix and NJOY sued the FDA to force reviews within the 180-day statutory timeframe; the FDA then announced it would pursue new PMTA rulemaking, which Altria welcomes.
- Illicit vapes: enforcement is having an effect; Altria estimates about 20 million adult vapers, down 1 million year on year. NJOY ACE has been redesigned around the patents and Altria plans to return to e-vapor in a "disciplined" way.
- Smokeable: price realization 4.4%; Marlboro Cowboy Cut is in about 100,000 stores (about 75% of cigarette volume) and Marlboro reached about 60% of premium.
- Duty drawback on cigarette exports is building; the PMI contract manufacturing agreement starts in 2027. Altria declined to size the 2027 benefit.
- ABI adjusted equity earnings $191 million (+21.7%); over $6 billion returned to shareholders in nine months; debt/EBITDA 1.9x.

### [Altria Q2 2026 earnings call transcript](https://bullfincher.io/companies/altria-group/earnings-call/fy2026-q2)

Executive talk · Sal Mancuso, Chief Executive Officer · 2026-07-30

- Q2 2026 call (July 30, 2026): Sal Mancuso's first quarter as CEO, Heather Newman introduced as the new CFO. H1 adjusted diluted EPS +4.9% to $2.80; nearly $3.9 billion returned to shareholders in the first half.
- on! PLUS went national in about 120,000 stores (covering about 90% of nicotine product volume, per Mancuso); on! retail share rose to 8.6% in Q2 and Altria credits the NICOSILK soft pouch. Q2 on! shipments fell 4.2% on trade inventory.
- Regulatory: the FDA's updated enforcement priorities are "a positive step"; the on! PLUS authorisations open a faster supplemental PMTA path for line extensions. NJOY ACE was modified so it no longer infringes the four patents, and a supplemental PMTA was submitted.
- Illicit vapes: federal seizures above $250 million in the quarter; about 20 million adult vapers, flat year on year.
- Smokeable adjusted OCI +2.4% to $3 billion in Q2, margin 64.8%; Marlboro Cowboy Cut launched for value-seeking premium smokers; Basic supported in about 35,000 stores; premium is about 85% of cigarette category profit.
- Guidance narrowed to $5.61-$5.72 adjusted EPS (+3.5% to 5.5%); about $1 billion of excess cash a year after the dividend goes to debt, buybacks or M&A.

## Questions about Altria

### What does Altria do?

Altria's operating companies make and sell nicotine products in the United States: Marlboro cigarettes, Black & Mild cigars, Copenhagen and Skoal smokeless tobacco, on! nicotine pouches and NJOY e-vapor.

### What is Altria's revenue?

FY2025 net revenues were $23,279 million, down 3.1%. Over the first nine months of 2026 net revenues were $17,671 million, up 1.4%.

### How many employees does Altria have?

About 5,900 people at December 31, 2025, 26% of them hourly unionised manufacturing employees.

### Who leads Altria?

Sal Mancuso became CEO after the May 14, 2026 annual meeting, succeeding William F. Gifford, Jr.; Heather Newman is CFO.

### What is Altria's strategy?

Its Vision, Moving Beyond Smoking, aims to transition adult smokers to smoke-free products such as on! and NJOY while keeping leadership in US tobacco and meeting its 2028 Enterprise Goals.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
